COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR BLOOD CANCERS: A SYSTEMATIC REVIEW

被引：0
|
作者：
Patel, N. [1 ]
Farid, S. [1 ]
Gomes, M. [1 ]
机构：
[1] UCL, London, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE320
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [41] HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER IN EUROPE, US, AND CANADA
    Stothard, C.
    Brown, A.
    Ralston, S.
    Curry, A.
    Cork, D.
    Hollier-Hann, G.
    VALUE IN HEALTH, 2020, 23 : S468 - S468
  • [42] Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed
    Rossig, Claudia
    Pearson, Andrew D.
    Vassal, Gilles
    Scobie, Nicole
    Bird, Nick
    Blanc, Patricia
    Vormoor, H. Josef
    Calkoen, Friso G.
    Locatelli, Franco
    del Bufalo, Francesca
    Rives, Susana
    Jacoby, Elad
    Balduzzi, Adriana
    Bourquin, Jean-Pierre
    Baruchel, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (03)
  • [43] DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA
    Tully, S.
    Feng, Z.
    Grindrod, K.
    McFarlane, T.
    Chan, K.
    Wong, W. W.
    VALUE IN HEALTH, 2019, 22 : S521 - S521
  • [44] Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis
    Maleki, Saba
    Esmaeili, Zahra
    Seighali, Niloofar
    Shafiee, Arman
    Namin, Sara Montazeri
    Zavareh, Mohammad Amin Tofighi
    Khamene, Sima Shamshiri
    Mohammadkhawajah, Izat
    Nanna, Michael
    Alizadeh-asl, Azin
    M.Kwan, Jennifer
    Hosseini, Kaveh
    CARDIO-ONCOLOGY, 2024, 10 (01)
  • [45] REVIEW AND COMPARISON OF OVERALL SURVIVAL EXTRAPOLATION IN HEALTH TECHNOLOGY ASSESSMENTS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES (CAR-TS)
    Kasle, A.
    Qu, T.
    Meng, Y.
    VALUE IN HEALTH, 2020, 23 : S20 - S20
  • [46] Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy
    Figura, N.
    Jain, M.
    Sim, A.
    Dean, E.
    Balagurunathan, Y.
    Chavez, J.
    Shah, B.
    Khimani, F.
    Lazaryan, A.
    Davila, M.
    Liu, H.
    Kim, S.
    Locke, F.
    Robinson, T.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S311 - S312
  • [47] Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
    Dhawale, Tejaswini
    Johnson, P. Connor
    Boateng, Kofi
    Barata, Anna
    Traeger, Lara
    Nelson, Ashley M.
    Lavoie, Mitchell W.
    Holmbeck, Katherine
    Choe, Joanna
    Nabily, Anisa
    Tripathi, Astha
    Amonoo, Hermioni L.
    Frigault, Matt
    El-Jawahri, Areej
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (04): : 402.e1 - 402.e12
  • [48] T-cell Immunotherapy and Cardiovascular Disease Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies
    Stein-Merlob, Ashley F.
    Ganatra, Sarju
    Yang, Eric H.
    HEART FAILURE CLINICS, 2022, 18 (03) : 443 - 454
  • [49] Outpatient vs Inpatient Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Cancer Patients: Systematic Literature Review
    Hansen, Doris
    Liu, Yi-Hsuan
    Ranjan, Sandip
    Bhandari, Hitesh
    Potluri, Ravi
    McFarland, Lindsay
    De Braganca, Kevin
    Huo, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S531 - S531
  • [50] Lymphapheresis Yields in the Production of Chimeric Antigen Receptor (CAR) T-Cell Therapy
    Allen, E. S.
    Cantilena, C.
    TRANSFUSION, 2015, 55 : 102A - 103A
12345